Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage ...

Research team at OncoRay identifies MMP11 as a promising biomarker for liquid biopsy in prostate cancer Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In ...

The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...

Study found men with low testosterone levels were associated with a 60% higher likelihood that prostate cancer managed on active surveillance would progress to a more aggressive state over time ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...

The new drug, known as VIR-5500, uses a so-called cloaking device and only activates when it reaches the tumour ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...

While many people are familiar with mammograms and smear tests, prostate screening is talked about far less. To shed light on this important subject ahead of Prostate Cancer Awareness Month in March, ...

Prostate cancer is one of the most common cancers affecting men around the world. In many countries, including Germany, it is the most frequently diagnosed cancer in men. Each year, about 65,000 men ...